drugset
drugset / Trial / NCT04493567

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

NCT04493567 ↗

Phase 1 Completed 102 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to develop an auto-injector (AI) device for the BMS-986036 subcutaneous formulation that can be self-administered conveniently by participants.

Timeline

Start
2020-07-29
Primary completion
2021-06-11
Completion
2021-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegbelfermin Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.